Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint

References

• Antoniou, M., A. L. Jorgensen, R. Kolamunnage-Dona, and H. P. Soyer. 2016. Biomarker-guided adaptive trial designs in phase II and phase III: A methodological review. PloS One 11 (2):e0149803. doi:10.1371/journal.pone.0149803.
   PubMed Web of Science ®Google Scholar
• Bratman, S. V., S. C. Yang, M. A. Iafolla, Z. Liu, A. R. Hansen, P. L. Bedard, S. Lheureux, A. Spreafico, A. A. Razak, S. Shchegrova, et al. 2020. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 1(9):873–881. doi:10.1038/s43018-020-0096-5.
   PubMedGoogle Scholar
• Burger, J. A., P. M. Barr, T. Robak, C. Owen, P. Ghia, A. Tedeschi, O. Bairey, P. Hillmen, S. E. Coutre, S. Devereux, et al. 2020. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34 (3):787–798. doi:10.1038/s41375-019-0602-x.
   PubMed Web of Science ®Google Scholar
• Dai, T., and S. Shete. 2016. Time-varying SMART design and data analysis methods for evaluating adaptive intervention effects. BMC Medical Research Methodology, 16(1): 1–17. doi: 10.1186/s12874-016-0202-7
   PubMedGoogle Scholar
• Dumville, J. C., S. Hahn, J. N. V. Miles, and D. J. Torgerson. 2006. The use of unequal randomisation ratios in clinical trials: A review. Contemporary Clinical Trials, 27(1): 1–12. doi: 10.1016/j.cct.2005.08.003
   PubMed Web of Science ®Google Scholar
• Feng, W., and A. S. Wahed. 2008. Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies. Biometrika 95 (3):695–707. doi:10.1093/biomet/asn025.
   Web of Science ®Google Scholar
• Insel, T. R. 2006. Beyond efficacy: The STAR* D trial. American Journal of Psychiatry 163 (1):5–7. doi:10.1176/appi.ajp.163.1.5.
   PubMed Web of Science ®Google Scholar
• Janiaud, P., S. Serghiou, and J. P. Ioannidis. 2019. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 73:20–30. doi:10.1016/j.ctrv.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Kidwell, K. M., M. A. Postow, and K. S. Panageas. 2018. Sequential, multiple assignment, randomized trial designs in immuno-oncology research. Clinical Cancer Research 24 (4):730–736. doi:10.1158/1078-0432.CCR-17-1355.
   PubMed Web of Science ®Google Scholar
• Kidwell, K. M., N. J. Seewald, Q. Tran, C. Kasari, and D. Almirall. 2018. Design and analysis considerations for comparing dynamic treatment regimens with binary outcomes from sequential multiple assignment randomized trials. Journal of Applied Statistics 45 (9):1628–1651. doi:10.1080/02664763.2017.1386773.
   PubMed Web of Science ®Google Scholar
• Lavori, P. W., and R. Dawson. 2000. A design for testing clinical strategies: Biased adaptive within‐subject randomization. Journal of the Royal Statistical Society: Series A (Statistics in Society) 163 (1):29–38. doi:10.1111/1467-985X.00154.
   Google Scholar
• Li, Z., and S. A. Murphy. 2011. Sample size formulae for two-stage randomized trials with survival outcomes. Biometrika, 98(3): 503–518. doi: 10.1093/biomet/asr019
   PubMed Web of Science ®Google Scholar
• Nahum-Shani, I., M. Qian, D. Almirall, W. E. Pelham, B. Gnagy, G. A. Fabiano, J. G. Waxmonsky, J. Yu, and S. A. Murphy. 2012. Experimental design and primary data analysis methods for comparing adaptive interventions. Psychological Methods 17 (4):457. doi:10.1037/a0029372.
   PubMed Web of Science ®Google Scholar
• Oetting, A. I., and J. A. Levy. 2007. Statistical methodology for a SMART design in the development of adaptive treatment strategies. In Shrout, P.E., Keyes, K.M., Ornstein, K. Causality and Psychopathology 8, pp. 179–204. Arlington: Oxford University Press.
   Google Scholar
• Orellana, L., A. Rotnitzky, and J. M. Robins. 2010. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part II: Proofs of results. The International Journal of Biostatistics 6 (2). doi:10.2202/1557-4679.1242.
   Google Scholar
• Robins, J. M., A. Rotnitzky, and L. P. Zhao. 1994. Estimation of regression coefficients when some regressors are not always observed. Journal of the American Statistical Association 89 (427):846–866. doi:10.1080/01621459.1994.10476818.
   Web of Science ®Google Scholar
• Ruppert, A. S., J. Yin, M. Davidian, A. A. Tsiatis, J. C. Byrd, J. A. Woyach, and S. J. Mandrekar. 2019. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. Annals of Oncology 30 (4):542–550. doi:10.1093/annonc/mdz053.
   PubMed Web of Science ®Google Scholar
• Seewald, N. J., 2016. Sample size calculator for SMARTs with binary or continuous outcomes. Available at https://nseewald1.shinyapps.io/SMARTsize/.
   Google Scholar
• Stone, R. M., D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al. 2001. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood, the Journal of the American Society of Hematology. 98(3):548–553. doi:10.1182/blood.V98.3.548.
   Google Scholar
• Tang, X., and M. Melguizo. 2015. DTR: An R package for estimation and comparison of survival outcomes of dynamic treatment. Journal of Statistical Software 65 (1):1–28. doi:10.18637/jss.v065.i07.
   Google Scholar
• Tummarello, D., D. Mari, F. Graziano, P. Isidori, G. Cetto, F. Pasini, A. Santo, and R. Cellerino. 1997. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV‐E) or teniposide (CAV‐T), followed by recombinant interferon‐α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Cancer: Interdisciplinary International Journal of the American Cancer Society 80 (12):2222–2229.
   Google Scholar
• Weiss, G. J., J. Beck, D. P. Braun, K. Bornemann-Kolatzki, H. Barilla, R. Cubello, W. Quan, A. Sangal, V. Khemka, J. Waypa, et al. 2017. Tumor cell–free DNA copy number instability predicts therapeutic response to immunotherapy. Clinical Cancer Research. 23(17):5074–5081. doi:10.1158/1078-0432.CCR-17-0231.
   PubMed Web of Science ®Google Scholar
• Wolbers, M., and J. D. Helterbrand. 2008. Two‐stage randomization designs in drug development. Statistics in Medicine 27 (21):4161–4174. doi:10.1002/sim.3309.
   PubMed Web of Science ®Google Scholar